News | June 02, 2025
Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Allopurinol is used to prevent or lower high uric acid levels in the blood
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
EBITDA before special items decreases to €4.08 billion (7.4%)
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Subscribe To Our Newsletter & Stay Updated
